MPLA TLR4 Agonist Modulation of AMPA/NMDA Ratio for Addiction Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cocaine addiction lack effective FDA-approved medications, and existing methods fail to adequately address the underlying neurochemical changes in the brain that contribute to behavioral sensitization and addiction.

Innovation Solution

Administration of a Toll-like receptor 4 (TLR4) agonist, specifically monophosphoryl lipid A (MPLA), to reduce the AMPA/NMDA ratio in D1-type medium spiny neurons, thereby reducing the likelihood of developing or redeveloping drug addiction and treating existing addiction by modulating inflammatory signals and synaptic strength.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If TLR4 agonist (MPLA) is administered to reduce AMPA/NMDA ratio and suppress behavioral sensitization, then therapeutic effectiveness for cocaine addiction is improved, but risk of inducing sickness behavior may worsen

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidsickness behavior

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent administers TLR4 agonist at controlled doses and timing parameters to achieve therapeutic effect while avoiding sickness behavior. The parameter optimization involves dosing regimens that stimulate sufficient TNFα production to reduce AMPA/NMDA ratio without excessive activation that would cause sickness behavior

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

TLR4 agonist acts as an intermediary substance that indirectly modulates the AMPA/NMDA ratio through TNFα production rather than directly affecting neuronal receptors. This intermediary mechanism allows for more controlled and selective modulation of synaptic plasticity pathways associated with addiction while minimizing off-target effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If conventional treatments are used for cocaine addiction, then ease of operation is maintained, but therapeutic effectiveness deteriorates due to lack of FDA-approved medications

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtreatment accessibility

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

MPLA is a multi-functional compound that serves both as a vaccine adjuvant (FDA-approved) and as a treatment for cocaine addiction. This universality allows the same substance to be used across different medical applications, facilitating easier adoption and reducing regulatory barriers

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If repeated exposure to drugs of abuse occurs, then behavioral sensitization develops, but this leads to increased likelihood of addiction and worsened treatment outcomes

Engineering Contradiction:

Improveprevention of behavioral sensitizationVSAvoidlong-term brain changes

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies TLR4 agonist treatment during the withdrawal phase or before relapse occurs, performing a preliminary protective action that prevents the consolidation of maladaptive synaptic changes. By intervening at this critical window, the treatment blocks the formation of long-lasting behavioral sensitization before it becomes entrenched

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

MPLA effectively decreases behavioral sensitization to cocaine by increasing TNFα levels, reducing AMPA/NMDA ratios, and suppressing drug-induced behavioral sensitization, offering a potential treatment for cocaine addiction without inducing sickness behavior.

Implementation Method 1

Monophosphoryl lipid A (MPLA) is a Toll-like receptor 4 agonist commonly used as a nontoxic, FDA-approved adjuvant in vaccines

Methodology Applied

Scientific EffectToll-like receptor 4 (TLR4) activation:

Implementation Method 2

MPLA...increases TNFα levels...reducing AMPA/NMDA ratios

Methodology Applied

Scientific EffectCytokine production (TNFα):

Data Source

PatentUS10328092B2Methods and compositions for treatment of drug addiction

Publication Date: 2019.06.25 MCGILL UNIV

AI summary

Methods of reducing AMPA/NMDA ratio in D1-type medium spiny neurons (MSN) and/or reducing development of behavioral sensitization or suppressing drug induced behavioral sensitization in a subject, optionally a subject that is afflicted with an addiction, the method comprising administering to the subject in need thereof an effective amount of a Toll-like receptor 4 (TLR4) agonist or a composition comprising said TLR4 agonist, preferably wherein the TLR4 agonist is a monophosphoryl lipid A (MPLA).